Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.

SFX


Data di pubblicazione: 2019
Titolo: Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide
Autori: 
Giammanco, Antonina
CEFALU', Angelo Baldassare
NOTO, Davide
AVERNA, Maurizio
Citazione: Giammanco, A., Cefalù, A., Noto, D., & Averna, M. (2019). Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide. CURRENT MEDICINAL CHEMISTRY.
Rivista: 
CURRENT MEDICINAL CHEMISTRY  
Digital Object Identifier (DOI): 10.2174/0929867326666190121120735
Abstract: Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.
Appare nelle tipologie:1.01 Articolo in rivista

File in questo prodotto:
FileDescrizioneTipologiaLicenza 
Therapeutic Options for Homozygous Familial Hypercholesterolemia_correted proof.pdf Pre-printAdministrator   Richiedi una copia
Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/10447/387950
  • Citazioni
  • ND
  • ND

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2020